A novel XIAP mutation in a Japanese boy with recurrent pancytopenia and splenomegaly X-linked lymphoproliferative syndrome (XLP) is a rare inherited primary immunodeficiency. It is clinically characterized by hemophagocytic lymphohistiocytosis (HLH), which usually develops in response to an Epstein-Barr virus (EBV) infection, dysgammaglobulinemia and malignant lymphoma. Most cases of XLP are caused by mutation in the SLAM-associated protein (SAP) or SH2D1A [1] [2] [3] . The X-linked inhibitor of apoptosis (XIAP) is also reported to cause XLP, 4 and at least 9 families with XIAP deficiency have been reported in Europe and the United States. 4, 5 This report describes a Japanese boy with recurrent HLH and splenomegaly, and identifies a novel mutation in the XIAP gene.
A 3-year old boy was admitted to Kyoto Prefectural University Hospital because of fever and pancytopenia. The patient presented with splenomegaly, lymphadenopathy and pancytopenia at the age of 20 months. Epstein-Barr virus (EBV) serological tests disclosed a primary EBV infection. He was clinically diagnosed with EBV-associated HLH, and was treated with prednisolone and thereafter showed some improvement. The patient again presented with pancytopenia at the age of 23 months followed by a measles-rubella vaccination. He had frequently experienced mild pancytopenia and splenomegaly followed by infections. A physical examination at the time of admission revealed a temperature of 38.2°C, a right cervical lymphadenopathy and splenomegaly, but neither hepatomegaly nor skin eruptions. Laboratory tests showed a white blood cell count of 3.1×10 9 /L with 44% neutrophils, 52% lymphocytes, 2% monocytes and 2% atypical lymphocytes, hemoglobin 10.0 g/dL, platelets of 111×10 9 /L, lactate dehydrogenase 1,261 IU/L, ferritin 2,240 ng/mL (normal: <480), triglyceride 220 mg/dL (normal: <149), and soluble interleukin-2 receptor 1,700 U/mL (normal: <466). The serum immunoglobulin levels were within normal ranges (IgG; 1,362 mg/dL, IgA; 129 mg/dL, IgM; 175 mg/dL). EBV-DNA was detected in whole blood but showed low copies (48 copies/μgDNA).
The patient was clinically diagnosed with mild HLH, and he was first treated with prednisolone alone, but had only a partial response. Treatment with cyclosporine A and dexamethasone improved his condition and resulted in a decreased spleen size. The patient is scheduled to receive hematopoietic stem cell transplantation to achieve a complete remission in the near future.
Although the patient had no family history of HLH, his recurrent episodes of HLH implied that this might be caused by a genetic defect. No mutations were identified in the causative genes for familial HLH including perforin, Munc13-4 and syntaxin 11. Another possible genetic disease was XLP. The flow cytometric detection of SAP and XIAP was used to screen for XLP, as previously described. 5, 6, 7 The patient showed normal expression of SAP in lymphocytes, but clearly had deficient expression of XIAP, suggesting XIAP deficiency ( Figure 1 ). Intriguingly, his mother showed bimodal expression of XIAP protein in lymphocytes, suggesting an obligate carrier. A gene analysis of XIAP was performed with parental informed consent, which disclosed a novel nonsense mutation (840C>T, R238X) in the patient (data not shown). The mother showed heterozygous alleles in this position.
The causative gene for XLP was SAP or SH2D1A (type 1)
1-3 and XIAP (type 2). 4 Both types of XLP can be identified by genetic analysis even in a sporadic case. However, the genetic analysis is labor-intensive and time-consuming. A flow cytometric screening for XIAP deficiency has been recently reported. 5 The present case was first screened by flow cytometry and was later confirmed by genetic analysis. The patient had 840C>T, thus resulting in R238X. Nine mutations have been identified in the XIAP gene (2 missense mutations, 3 nonsense mutations, one small deletion and 3 large deletions). 4, 5 The nonsense mutations include Q104X, E118X and Q333X and also R238X which is a novel mutation.
Both SAP deficiency and XIAP deficiency result in XLP, but they are described as clinically indistinguishable. However, lymphoma has so far not been described and only about 50% had EBV-HLH in XIAP deficient patients.
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In addition, patients with XIAP deficiency often have splenomegaly, unlike patients with SAP deficiency. Clinical manifestations of splenomegaly may be typical signs of XIAP deficiency, as demonstrated in the present case. EBV-HLH in SAP deficiency usually results in a fatal course, but the present case showed a mild course of EBV-HLH. EBV-HLH in XIAP deficiency may, therefore, show a milder presentation than that of SAP deficiency. To clarify the differences in the clinical picture of SAP deficiency and XIAP deficiency, a greater number of patients with XLP should be surveyed. Mutations of the Shwachman-Bodian-Diamond syndrome gene in patients presenting with refractory cytopenia -do we have to screen?
Children diagnosed with acquired hypocellular myelodysplastic syndrome (MDS), such as refractory cytopenia (RC), share clinical features with patients suffering from inherited bone marrow failure (IBMF). The Shwachman-Diamond syndrome (SDS; OMIM #260400) is an autosomal recessive disorder associated with bone marrow failure, pancreatic exocrine insufficiency, short stature and liver abnormalities. Other symptoms, such as eczematous lesions, oral disease, cognitive/behavioral problems, immune dysfunction or urinary tract anomalies, may occur.
1 In addition, SDS predisposes to the development of leukemia.
1 Mutations in the Shwach manBodian-Diamond Syndrome gene (SBDS) are found in approximately 90% of SDS patients.
2 Studies in yeast suggest an important role of the SBDS protein in RNA metabolism. Letters to the Editor 
